Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 687129
                    [Title] => Roche partners with Merck vs chronic hepatitis C
                    [Summary] => 
Roche has announced that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness of chronic hepatitis C (HCV) infection in the United States.
                    [DatePublished] => 2011-05-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 16664
                    [Title] => Tolerability key to success of hepatitis C treatment
                    [Summary] => 
            
                    [DatePublished] => 2007-09-27 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 300282
                    [Title] => New hepa B treatment outdoes standard care
                    [Summary] => A recent study shows that peginterferon alfa 2-a, a new hepatitis B treatment, provides a significantly greater proportion of patients with lasting remission compared to lamivudine, the current standard of care. 


A study was conducted among patients with HbeAG positive hepatitis B, the subtype of the disease which affects majority of hepatitis B patients worldwide.


                    [DatePublished] => 2005-10-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 274759
                    [Title] => New hepa B treatment cited
                    [Summary] => At the recent 14th biennial conference of the Asian Pacific Association for the Study of the Liver, a new hepatitis B treatment option was cited. 


Peginterferon alfa 2-a has been shown to treat both HbeAG-positive and HbeAG-negative chronic hepatitis B, thus removing the need for daily and potentially life-long therapy for the disease.


The studies presented during the conference showed that peginterferon alfa 2-a is superior to lamivudine, the most commonly prescribed medication for hepatitis B. 


                    [DatePublished] => 2005-04-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

PEGINTERFERON

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 687129
                    [Title] => Roche partners with Merck vs chronic hepatitis C
                    [Summary] => 
Roche has announced that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness of chronic hepatitis C (HCV) infection in the United States.
                    [DatePublished] => 2011-05-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 16664
                    [Title] => Tolerability key to success of hepatitis C treatment
                    [Summary] => 
            
                    [DatePublished] => 2007-09-27 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 300282
                    [Title] => New hepa B treatment outdoes standard care
                    [Summary] => A recent study shows that peginterferon alfa 2-a, a new hepatitis B treatment, provides a significantly greater proportion of patients with lasting remission compared to lamivudine, the current standard of care. 


A study was conducted among patients with HbeAG positive hepatitis B, the subtype of the disease which affects majority of hepatitis B patients worldwide.


                    [DatePublished] => 2005-10-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 274759
                    [Title] => New hepa B treatment cited
                    [Summary] => At the recent 14th biennial conference of the Asian Pacific Association for the Study of the Liver, a new hepatitis B treatment option was cited. 


Peginterferon alfa 2-a has been shown to treat both HbeAG-positive and HbeAG-negative chronic hepatitis B, thus removing the need for daily and potentially life-long therapy for the disease.


The studies presented during the conference showed that peginterferon alfa 2-a is superior to lamivudine, the most commonly prescribed medication for hepatitis B. 


                    [DatePublished] => 2005-04-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche partners with Merck vs chronic hepatitis C

May 19, 2011 - 12:00am

Roche has announced that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness of chronic hepatitis...

Science and Environment

Tolerability key to success of hepatitis C treatment

September 27, 2007 - 12:00am

Science and Environment

New hepa B treatment outdoes standard care

October 6, 2005 - 12:00am

A recent study shows that peginterferon alfa 2-a, a new hepatitis B treatment, provides a significantly greater proportion of patients with lasting remission compared to lamivudine, the current standard of care....

Science and Environment

New hepa B treatment cited

April 21, 2005 - 12:00am

At the recent 14th biennial conference of the Asian Pacific Association for the Study of the Liver, a new hepatitis B treatment option was cited. Peginterferon alfa 2-a has been shown to treat both HbeAG-positive...

Science and Environment